Table 2.
Detailed information and serological profiles of five children from Kimberley, South Africa, with serological evidence of current or previous infection with HBV (based on positive HBsAg (n = 3) and/or anti-HBc (n = 3))
| Subject ID | K306 | K405 | KReC51 | KReC151 | K093 |
|---|---|---|---|---|---|
| Cohort | HIV+ age ≤ 60 months | HIV+ age ≤ 60 months | KReC | KReC | HIV+ age > 60 months |
| Sex | F | F | F | M | F |
| Age (months) at time of sampling | 18 | 37 | 20 | 15 | 118 |
| HIV infection | Positive | Positive | Negative | Negative | Positive |
| ARTa (if HIV positive) | Yes | Yes | n/a | n/a | No |
| Number of doses of HBV vaccine | NK | NK | NK | 3 | NK |
| HBsAg resultb | Detected | Detected | Detected | Not detected | Not detected |
| Anti-HBc resultc | Not detected | Not detected | Detected | Detected | Detected |
| HBeAg resultd | Not done | Not done | Detected | Not done | Not done |
| Anti-HBs resulte | Not detected | Not detected | Not detected | Detected | Not detected |
| Interpretation | Active infection | Active infection | Active infection | Immunised, infected and cleared | Infected and cleared |
aART indicates the participant was receiving anti-retroviral therapy to treat HIV infection; bhepatitis B surface antigen test; chepatitis B core antibody test; dhepatitis B envelope antigen test; ehepatitis B surface antibody test (vaccine mediated response). KReC Kimberley Respiratory Cohort, n/a not applicable, NK not known